Trevi Therapeutics Inc. (TRVI)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond
Trevi Therapeutics (TRVI) is initiated with a "Buy" rating, driven by its lead asset Haduvio's advancement toward phase 3 testing for chronic cough in IPF. Company's Haduvio demonstrated statistically significant efficacy in phase 2b CORAL study [IPF] and phase 2a RIVER [RCC], with a differentiated dual central/peripheral mechanism of action. The company is well-capitalized, with $194.9M in cash and a projected runway into 2028, supporting upcoming pivotal trials.
Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript
Trevi Therapeutics, Inc. ( TRVI ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jennifer Good - Co-Founder, CEO, President, Interim Principal Financial Officer & Director James Cassella - Chief Development Officer Farrell Simon - Chief Commercial Officer Conference Call Participants Ryan Deschner - Raymond James & Associates, Inc., Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Judah Frommer - Morgan Stanley, Research Division Serge Belanger - Needham & Company, LLC, Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division William Wood - B. Riley Securities, Inc., Research Division Kaveri Pohlman - Clear Street LLC Presentation Operator Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2025 Earnings Conference Call.
Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants g - Corporate Participant e - Corporate Participant Farrell Simon - Chief Commercial Officer James V. Cassella - Chief Development Officer Jennifer L.
Trevi Therapeutics Inc. (TRVI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Trevi Therapeutics Inc. ever had a stock split?
Trevi Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jennifer L. Good CEO | NASDAQ (NMS) Exchange | 89532M101 CUSIP |
| US Country | 31 Employees | - Last Dividend | - Last Split | 7 May 2019 IPO Date |
Overview
Trevi Therapeutics, Inc. is a New Haven, Connecticut-based clinical-stage biopharmaceutical company dedicated to the advancement of innovative treatments for serious neurologically mediated conditions. With a focus on the development and commercialization of their lead product candidate, Haduvio, Trevi Therapeutics is pushing the boundaries of what is possible in the realm of neurologically based treatments. The company was formed in 2011 and has since been on a mission to bring relief to patients suffering from chronic conditions that are currently underserved by the medical community. Through rigorous research and clinical trials, Trevi Therapeutics aims to unlock new potential in the fight against challenging medical conditions, bolstered by a strategic license agreement with Endo Pharmaceuticals Inc.
Products and Services
- Haduvio (Oral Extended-release Nalbuphine) - This is Trevi Therapeutics' leading product candidate, currently undergoing extensive Phase IIb/III clinical trials to assess its efficacy and safety. Below are the primary areas of focus for Haduvio’s application:
- Chronic Pruritus: Pruritus, or intense itching, is a debilitating condition often associated with various underlying diseases. Haduvio is being developed to address this relentless itching, particularly when it becomes chronic and severely impacts the quality of life of patients.
- Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients: IPF is a fatal disease characterized by scarring of the lungs, leading to a progressive decline in lung function. Treatment options are limited, and the symptom of chronic cough significantly reduces patients' quality of life. Haduvio offers hope as a potential treatment to alleviate this distressing symptom.
Contact Information
